118 related articles for article (PubMed ID: 33184860)
1. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
[TBL] [Abstract][Full Text] [Related]
2. Brexpiprazole Prevents the Malignant Progression of Human Colorectal Cancer Cells and Increases Its Sensitivity to EGFR Inhibition.
Long X; Liu X; Xia W; Liu L; Chen W
Front Biosci (Landmark Ed); 2024 May; 29(5):174. PubMed ID: 38812296
[TBL] [Abstract][Full Text] [Related]
3. Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer.
Yang L; Bhattacharya A; Li Y; Sexton S; Ling X; Li F; Zhang Y
J Exp Clin Cancer Res; 2022 Jun; 41(1):184. PubMed ID: 35650607
[TBL] [Abstract][Full Text] [Related]
4. Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells.
Al-Aidaroos AQ; Yuen HF; Guo K; Zhang SD; Chung TH; Chng WJ; Zeng Q
J Clin Invest; 2013 Aug; 123(8):3459-71. PubMed ID: 23867504
[TBL] [Abstract][Full Text] [Related]
5. CircHIF1A induces cetuximab resistance in colorectal cancer by promoting HIF1α-mediated glycometabolism alteration.
Geng Y; Zheng X; Zhang D; Wei S; Feng J; Wang W; Zhang L; Wu C; Hu W
Biol Direct; 2024 May; 19(1):36. PubMed ID: 38715141
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab inhibits colorectal cancer development through inactivating the Wnt/β-catenin pathway and modulating PLCB3 expression.
Zhang X; Zhou W; Wu C; Jiang J; Guo Q; Feng L; Cheng X; Zhang X
Sci Rep; 2024 May; 14(1):10642. PubMed ID: 38724565
[TBL] [Abstract][Full Text] [Related]
7. Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer.
Knickelbein K; Tong J; Chen D; Wang YJ; Misale S; Bardelli A; Yu J; Zhang L
Oncogene; 2018 Aug; 37(33):4599-4610. PubMed ID: 29755130
[TBL] [Abstract][Full Text] [Related]
8. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.
Vangala D; Ladigan S; Liffers ST; Noseir S; Maghnouj A; Götze TM; Verdoodt B; Klein-Scory S; Godfrey L; Zowada MK; Huerta M; Edelstein DL; de Villarreal JM; Marqués M; Kumbrink J; Jung A; Schiergens T; Werner J; Heinemann V; Stintzing S; Lindoerfer D; Mansmann U; Pohl M; Teschendorf C; Bernhardt C; Wolters H; Stern J; Usta S; Viebahn R; Admard J; Casadei N; Fröhling S; Ball CR; Siveke JT; Glimm H; Tannapfel A; Schmiegel W; Hahn SA
Genome Med; 2021 Jul; 13(1):116. PubMed ID: 34271981
[TBL] [Abstract][Full Text] [Related]
9. The inhibitory effect of ECG and EGCG dimeric procyanidins on colorectal cancer cells growth is associated with their actions at lipid rafts and the inhibition of the epidermal growth factor receptor signaling.
Zhu W; Li MC; Wang FR; Mackenzie GG; Oteiza PI
Biochem Pharmacol; 2020 May; 175():113923. PubMed ID: 32217102
[TBL] [Abstract][Full Text] [Related]
10. RAC1B modulates intestinal tumourigenesis via modulation of WNT and EGFR signalling pathways.
Gudiño V; Pohl SÖ; Billard CV; Cammareri P; Bolado A; Aitken S; Stevenson D; Hall AE; Agostino M; Cassidy J; Nixon C; von Kriegsheim A; Freile P; Popplewell L; Dickson G; Murphy L; Wheeler A; Dunlop M; Din F; Strathdee D; Sansom OJ; Myant KB
Nat Commun; 2021 Apr; 12(1):2335. PubMed ID: 33879799
[TBL] [Abstract][Full Text] [Related]
11. A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming K-ras mutations and drug resistance in colorectal carcinoma.
Song H; Li H; Shen X; Liu K; Feng H; Cui J; Wei W; Sun X; Fan Q; Bao W; Zhou H; Qian L; Nie H; Cheng X; Du Z
Acta Biomater; 2024 Mar; 177():456-471. PubMed ID: 38331131
[TBL] [Abstract][Full Text] [Related]
12. Isthmin-1 promotes growth and progression of colorectal cancer through the interaction with EGFR and YBX-1.
Zhou X; Zhang K; Wang C; Teng Y; Yu P; Cai W; Gao W; Li M; Ding Y; Sun P; Chen F; Wang Y; Ma J; Maeshige N; Ma X; Li Q; Liang X; Zhang Y; Su D
Cancer Lett; 2024 May; 590():216868. PubMed ID: 38593920
[TBL] [Abstract][Full Text] [Related]
13. PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation.
Davis TB; Yang M; Schell MJ; Wang H; Ma L; Pledger WJ; Yeatman TJ
Sci Rep; 2018 Jun; 8(1):9296. PubMed ID: 29915291
[TBL] [Abstract][Full Text] [Related]
14. Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.
Woolston A; Khan K; Spain G; Barber LJ; Griffiths B; Gonzalez-Exposito R; Hornsteiner L; Punta M; Patil Y; Newey A; Mansukhani S; Davies MN; Furness A; Sclafani F; Peckitt C; Jiménez M; Kouvelakis K; Ranftl R; Begum R; Rana I; Thomas J; Bryant A; Quezada S; Wotherspoon A; Khan N; Fotiadis N; Marafioti T; Powles T; Lise S; Calvo F; Guettler S; von Loga K; Rao S; Watkins D; Starling N; Chau I; Sadanandam A; Cunningham D; Gerlinger M
Cancer Cell; 2019 Jul; 36(1):35-50.e9. PubMed ID: 31287991
[TBL] [Abstract][Full Text] [Related]
15. Metalloprotease ADAM9 cleaves ephrin-B ligands and differentially regulates Wnt and mTOR signaling downstream of Akt kinase in colorectal cancer cells.
Chandrasekera P; Perfetto M; Lu C; Zhuo M; Bahudhanapati H; Li J; Chen WC; Kulkarni P; Christian L; Liu J; Yien YY; Yu C; Wei S
J Biol Chem; 2022 Aug; 298(8):102225. PubMed ID: 35780836
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
Rio-Vilariño A; Cenigaonandia-Campillo A; García-Bautista A; Mateos-Gómez PA; Schlaepfer MI; Del Puerto-Nevado L; Aguilera O; García-García L; Galeano C; de Miguel I; Serrano-López J; Baños N; Fernández-Aceñero MJ; Lacal JC; Medico E; García-Foncillas J; Cebrián A
Br J Cancer; 2024 May; 130(8):1402-1413. PubMed ID: 38467828
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer.
Jones VT; Graves-Deal R; Cao Z; Bogatcheva G; Ramirez MA; Harmych SJ; Higginbotham JN; Sharma V; Damalanka VC; Wahoski CC; Joshi N; Irudayam MJ; Roland JT; Ayers GD; Liu Q; Coffey RJ; Janetka JW; Singh B
Cell Mol Life Sci; 2024 Jan; 81(1):28. PubMed ID: 38212428
[TBL] [Abstract][Full Text] [Related]
18. α-Hederin induces paraptosis by targeting GPCRs to activate Ca
Rao X; Li Z; Zhang Q; Lai Y; Liu J; Li L; Cheng H; Shen W; Sun D
Cancer Med; 2024 Apr; 13(8):e7202. PubMed ID: 38659391
[TBL] [Abstract][Full Text] [Related]
19. Morphine modulation of thrombospondin levels in astrocytes and its implications for neurite outgrowth and synapse formation.
Ikeda H; Miyatake M; Koshikawa N; Ochiai K; Yamada K; Kiss A; Donlin MJ; Panneton WM; Churchill JD; Green M; Siddiqui AM; Leinweber AL; Crews NR; Ezerskiy LA; Rendell VR; Belcheva MM; Coscia CJ
J Biol Chem; 2010 Dec; 285(49):38415-27. PubMed ID: 20889977
[TBL] [Abstract][Full Text] [Related]
20. Detection of genes responsible for cetuximab sensitization in colorectal cancer cells using CRISPR-Cas9.
Hu TT; Yang JW; Yan Y; Chen YY; Xue HB; Xiang YQ; Ye LC
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33048115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
